C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis

Chordomas are rare, locally aggressive malignancies that are often difficult to eradicate. Surgery and radiotherapy are the first-line treatments, but the probability of local recurrence is high. According to our previous research, c-Cbl and Cbl-b have been linked to tumor progression and poor prognosis of glioma. However, their role in skull base chordomas is unclear. To clarify this issue, in the present study, we analyzed the expression of c-Cbl and Cbl-b in relation to the clinicopathological features and clinical outcome of skull base chordoma patients (n = 70). C-Cbl and Cbl-b expression was evaluated by immunohistochemistry, and a survival analysis was performed based on clinical data. We found that c-Cbl and Cbl-b were upregulated in 30 of 70 (42.9%) and 32 of 70 (45.7%) patients with skull base chordomas, respectively. A Kaplan-Meier analysis and log-rank test indicated that high c-Cbl and Cbl-b levels were significantly associated with overall survival (P = .003 and P = .008, respectively) and progression-free survival (P < .001 and P = .022, respectively). These data indicated that c-Cbl and Cbl-b expression in skull base chordomas can predict tumor invasion and poor prognosis and is therefore a potential therapeutic target for chordoma treatment.